Wednesday, July 8, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Clinical program

TAK-385 40 mg

Phase 1 · small molecule · Japanese Premenopausal Healthy Adult Women

TAK-385 40 mg for Japanese Premenopausal Healthy Adult Women is a Phase 1 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).

← All Takeda projects Phase 1 small molecule completed

Internal code TAK-385-1011

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Takeda
Phase
Phase 1
Modality
small_molecule
Indication
Japanese Premenopausal Healthy Adult Women
Status
completed
Trials
1

Clinical trials